8-K: CytoSorbents Submits DrugSorb-ATR Application to FDA, Announces Preliminary Q3 Results

CytoSorbents has submitted its DrugSorb-ATR marketing application to the FDA and Health Canada, while also reporting preliminary Q3 2024 financial results including product sales and gross margin estimates.

Summary

• CytoSorbents has submitted a De Novo marketing application to the U.S. FDA for its DrugSorb-ATR device, intended to reduce bleeding in patients on ticagrelor undergoing heart bypass surgery.
• The FDA has granted DrugSorb-ATR Breakthrough Device Designation, which makes it eligible for priority review.
• The company has also completed its Health Canada Medical Device License application, pending receipt of Medical Device Single Audit Program certification.
• Regulatory decisions from both the FDA and Health Canada are expected in 2025.
• Preliminary Q3 2024 product sales are estimated to be between $8.3 million and $8.5 million, representing a 7% to 10% increase compared to Q3 2023.
• Product gross margins for Q3 2024 are estimated to be between 50% and 60%, down from 71% in Q3 2023 due to a temporary production slowdown and a short-term manufacturing issue.
• The company believes the manufacturing issue has been resolved and expects a return to normalized production levels and gross margins in Q4 2024.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the regulatory submissions and sales growth, but tempered by the significant drop in gross margins and the manufacturing issues.

Positives

• The submission of the DrugSorb-ATR application to the FDA is a major milestone for the company.
• The FDA's Breakthrough Device Designation for DrugSorb-ATR should expedite the review process.
• The company has completed its Health Canada Medical Device License application.
• Product sales are estimated to have grown by 7% to 10% in Q3 2024 compared to Q3 2023.
• The company believes the short-term manufacturing issue has been resolved and expects a return to normalized production levels and product gross margins in Q4 2024.

Negatives

• Product gross margins for Q3 2024 are estimated to be significantly lower than the previous year, at 50% to 60% compared to 71% in Q3 2023.
• A temporary slowdown in production and a short-term manufacturing issue impacted the number of CytoSorb devices produced in the quarter.

Risks

• The FDA and Health Canada regulatory approval processes are not guaranteed and may take longer than expected.
• The company's future financial performance is dependent on the successful commercialization of DrugSorb-ATR.
• The company experienced a short-term manufacturing issue that impacted production and gross margins in Q3 2024.
• The company's forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company expects to receive regulatory decisions from the FDA and Health Canada on DrugSorb-ATR in 2025 and anticipates a return to normalized production levels and product gross margins in Q4 2024.

Management Comments

• Dr. Phillip Chan, Chief Executive Officer, stated that the DrugSorb-ATR De Novo submission to FDA is the culmination of multiple years of significant clinical, regulatory, and manufacturing accomplishments.
• Dr. Phillip Chan also expressed pride in the CytoSorbents team and external collaborators for achieving this major milestone.

Industry Context

This announcement is significant for the medical device industry, particularly in the area of blood purification and the management of bleeding risks associated with blood thinning medications during surgery. The successful approval of DrugSorb-ATR could provide a new treatment option for patients undergoing CABG surgery while on ticagrelor.

Comparison to Industry Standards

• The submission of a De Novo application to the FDA is a significant step for a novel medical device like DrugSorb-ATR, as it indicates that there is no existing predicate device.
• The FDA's Breakthrough Device Designation is a positive sign, as it is intended to expedite the review process for devices that address unmet medical needs.
• The estimated Q3 2024 product sales growth of 7% to 10% is a positive indicator, but the significant decrease in gross margins from 71% to 50-60% is a concern.
• Companies like Baxter and Fresenius Medical Care are major players in the blood purification market, and CytoSorbents is attempting to carve out a niche with its unique technology.
• The 140 patient STAR-T trial is a significant investment in clinical research and is a key component of the regulatory submission.

Stakeholder Impact

• Shareholders may be concerned about the lower gross margins in Q3 2024.
• Patients may benefit from the potential approval of DrugSorb-ATR, which could reduce the risk of bleeding during heart surgery.
• Employees may be impacted by the production slowdown and manufacturing issues.

Next Steps

• The company will await feedback from the FDA on its DrugSorb-ATR De Novo application.
• The company will submit its Health Canada Medical Device License application upon receipt of MDSAP certification.
• The company expects to return to normalized production levels and product gross margins in Q4 2024.

Key Dates

Keywords

DrugSorb-ATR, FDA, Health Canada, Medical Device, De Novo, Ticagrelor, CABG, Blood Purification, CytoSorb, Regulatory Approval, Gross Margins, Product Sales